The clinical-stage biotech's long-running partnership with Amgen took another big step forward.
News & Analysis: Cytokinetics
CYTK earnings call for the period ending December 31 2018.
The biotech will join the S&P SmallCap 600 index.
What the biotech didn't say might have caused its downfall.
Cytokinetics Inc. shares jumped by over 10% earlier in the day after reporting financial results for 2015.
Shares of the clinical-stage biopharma Cytokinetics roared higher today. Here's why.
Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.
Find out which biotech posted the best, and worst, clinical results last week.
Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.
Cytokinetics reported disappointing midstage results for tirasemtiv, its experimental Lou Gehrig's disease drug. Is this dip a buying opportunity or your cue to stay far away?